The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

On April 29, 2026, Avory & Company, LLC disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 156,571 shares of Omnicell (NASDAQ:OMCL), an estimated $6.55 million transaction based on the quarterly average price.

According to its SEC filing dated April 29, 2026, Avory & Company, LLC reduced its position in Omnicell by 156,571 shares, an estimated $6.55 million transaction based on the average first-quarter 2026 closing price. The quarter-end value of the Omnicell stake declined by $8.01 million, a figure that reflects both the reduction in shares and Omnicell’s price movement over the period. The fund’s post-sale holding in Omnicell was 77,137 shares, valued at $2.57 million.

Following the sale, Omnicell represents 3.33% of Avory & Company, LLC’s reportable assets under management.

Top five holdings after the filing:

NYSEMKT: VOO: $17.22 million (22.3% of AUM)

NASDAQ: ZM: $8.59 million (11.1% of AUM)

NYSE: XYZ: $7.41 million (9.6% of AUM)

BATS: AVRY: $7.29 million (9.4% of AUM)

NASDAQ: Z: $4.27 million (5.5% of AUM)

As of April 28, 2026, Omnicell shares were priced at $45.51, up 47.6% over the past year, outperforming the S&P 500 by 18.45 percentage points.

Metric

Value

Revenue (TTM)

$1.19 billion

Net income (TTM)

$2.052 million

Market capitalization

$2.07 billion

Price (as of market close April 28, 2026)

$45.51

Omnicell provides medication management solutions, including automated dispensing systems, pharmacy automation, and adherence packaging for healthcare systems and pharmacies

The company generates revenue primarily through the sale and servicing of automation equipment, software solutions, and related consumables that optimize medication distribution and inventory management

Its primary customers are hospitals, health systems, institutional pharmacies, and retail pharmacies seeking to improve medication safety, efficiency, and regulatory compliance

Omnicell operates at scale in the healthcare technology sector, serving over 3,600 employees and generating more than $1.20 billion in annual revenue. The company's strategy centers on delivering integrated automation and software solutions that streamline medication management across care settings. Omnicell's competitive edge lies in its comprehensive product suite and focus on workflow automation, which enables healthcare providers to enhance patient safety and operational efficiency.

Avory & Company, a Florida-based investment advisor, recently disclosed the sale of approximately $6.6 million worth of Omnicell stock during the first quarter (the three months ending on March 31, 2026). Here are some key takeaways for investors.

First, Omnicell stock has struggled over the last few years. Since 2021, shares have declined by 68%, with a compound annual growth rate (CAGR) of -20.8%. That’s well below the return produced by the S&P 500 over the same period — a 83% total return and a CAGR of 12.8%.

At any rate, Omnicell recently reported strong first-quarter earnings, led by $310 million in revenue (up 15% year-over-year). Net income was $11 million, up from a net loss of -$7 million one year ago.

In summary, Omnicell stock is enjoying a boost from a positive earnings report. However, the stock’s long-term track record of underperformance may give some investors pause.

Before you buy stock in Omnicell, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Omnicell wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $497,606!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,306,846!*

Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of April 29, 2026.

Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Block, Vanguard S&P 500 ETF, Zillow Group, and Zoom Communications. The Motley Fool has a disclosure policy.

Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing was originally published by The Motley Fool